REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant
Study Details
Study Description
Brief Summary
This research study will evaluate the effectiveness of postoperative administration of a drug called suvorexant, to improve postoperative sleep and decrease the severity of delirium (serious confusion) in adults 65 years and older undergoing non-cardiac surgery.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Suvorexant is an FDA-approved drug to treat a condition called insomnia, a sleep disorder characterized by difficulty falling asleep, staying asleep or getting good quality sleep, and has been found to have a good safety profile in older adults. Since older surgical patients often have difficulties with sleep, suvorexant might improve sleep after surgery but this remains unknown. Because difficulties with sleeping after surgery have been associated with a disorder of severe confusion called delirium, administration of suvorexant after surgery may also help prevent delirium or decrease its severity.
Participants will receive either a placebo or suvorexant by mouth (or feeding tube if present) on the first three nights after surgery while in the hospital. Prior to surgery, participants will be asked to wear a wristband sleep monitor and complete several questionnaires about their sleep, brief thinking and memory tests, a test of attention, and a measurement of their pupil size with a special camera. After surgery, participants will wear a comfortable headband device that records the electrical signals from the brain to measure the amount and depth of their sleep. This device will be worn for the first 3 nights from 9:00 PM to 6:00 AM after surgery or until hospital discharge, whichever occurs first. After surgery, participants will also answer several questions about their sleep quality and redo some of the brief thinking and memory tests (delirium tests), attention tests, and pupil size measurements. Additionally, the investigators will collect a blood sample prior to surgery and on the first two days after surgery.
Benefits of this study include the possibility of improved sleep after surgery and fewer problems with confusion and thinking and memory problems after surgery.
Risks of participation include headache, diarrhea, dry mouth, cough, abnormal dreams, dizziness, daytime tiredness and discomfort from the blood draw.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Suvorexant Arm
|
Drug: Suvorexant 20 mg
Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, &2
|
| Placebo Comparator: Placebo Arm
|
Drug: Placebo
Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, &2
|
Outcome Measures
Primary Outcome Measures
- Total Sleep Time [Post operative Day 0-2]
Total sleep time (TST) on first postoperative night that patient received study drug, as measured by electroencephalography (EEG). Total sleep time includes amount of time in sleep during the lights out period (defined between 21:00 and 06:00).
Secondary Outcome Measures
- Postoperative Delirium Severity score [Postoperative Day 0 through Day 5 or discharge, whichever occurs first.]
1. Three minute Confusion Assessment Method (3D-CAM ) severity scores up through postoperative day 5 or discharge, whichever occurs first, in patients receiving suvorexant vs placebo. Scores range from 0-20 and the higher score is worse.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 65 and older
-
Undergoing non-cardiac, non-intracranial surgery, any surgical procedure not involving the skull, brain, cerebrovascular structures
-
Scheduled postoperative inpatient overnight stay
-
Able to give informed consent or has legally authorized representative able to give informed consent on their behalf
-
English-speaking
Exclusion Criteria:
-
Inmate of correctional facility
-
Body mass index> 40
-
Legal blindness
-
Unable to perform study related questionnaires and assessments
-
Use of outpatient sedating sleep aids > 2 times per any week in 1 month preceding day of surgery. Sedating sleep aids, listed in section 5.5.
-
History of psychotic disorder, including schizophrenia, schizoaffective disorder, schizophreniform or brief psychotic disorder.
-
History of liver failure with documented international normalized ratio (INR) of >1.2 or with history of hepatic encephalopathy
-
History of severe sleep apnea or obesity hypoventilation syndrome requiring home bilevel positive airway pressure therapy or home ventilator or other forms of noninvasive ventilation
-
Chronic lung disease requiring home oxygen therapy
-
History of narcolepsy
-
Use of systemic (oral, intravenous, intramuscular, subcutaneous) moderate or strong CYP3A inhibitors within 1 week prior to surgery, listed in section 5.5.
-
Current or planned administration of digoxin, or is currently experiencing digoxin toxicity
-
Undergoing surgery that will result in inability to take medications by mouth including laryngectomy, tracheostomy, and oral resection/reconstructive surgery
-
Undergoing surgery that will require postoperative strict bowel rest, including gastrectomy, esophagectomy, and pancreaticoduodenectomy
-
Undergoing surgery in an area that will make it unsafe to wear a headband, such as scalp or forehead procedures.
-
Inappropriate for study inclusion based on the judgement of the principal investigator
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Duke University Medical Center | Durham | North Carolina | United States | 27710 |
Sponsors and Collaborators
- Duke University
- Merck Sharp & Dohme LLC
Investigators
- Principal Investigator: Michael Devinney Jr, MD, PhD, Duke University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Pro00111869